scPharmaceuticals said today that it closed a $45.6 million Series B round, co-led by OrbiMed and a subsidiary of Sun Pharmaceutical Industries. Other investors included 5AM Ventures and Lundbeckfond Ventures.
The investment will be used to support the development of the operational and commercial infrastructure needed to bring Furoscix and the sc2Wear Infusor to market in the U.S., the company said.
Get the full story at our sister site, Drug Delivery Business News.
The post scPharmaceuticals closes $46m Series B round appeared first on MassDevice.